<DOC>
	<DOCNO>NCT01134640</DOCNO>
	<brief_summary>A post marketing surveillance , prospective study collect safety information 250 subject epidermal growth factor receptor ( EGFR ) expressing , KRAS wild-type metastatic colorectal cancer treat Erbitux final evaluable case .</brief_summary>
	<brief_title>A Post-Marketing Surveillance Study On ErbituxÂ® ( Cetuximab ) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>EGFR expressing , KRAS wildtype subject metastatic colorectal cancer , indicate Erbitux treatment accord nationally authorize label ( combination irinotecan , metastatic colorectal cancer failure irinotecanincluding cytotoxic therapy ) Subjects eligible Erbitux treatment accord indication national label ; hypersensitivity reaction ( grade 3 4 ) Erbitux</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>mCRC</keyword>
	<keyword>post marketing surveillance</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>KRAS</keyword>
</DOC>